Junjie Shan

Junjie Shan


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
YWYajun Wu
Yajun Wu
SLShuai Li
Shuai Li
HLHaixia Li
Haixia Li
CZChunzhi Zhao
Chunzhi Zhao
HMHao Ma
Hao Ma
YWYuxia Wang
Yuxia Wang

1 September 2019 in Virus Research
Verified
Journal Article
Closed access
WZWeijiao Zhang
Weijiao Zhang
NCNan Cheng
Nan Cheng
YWYuxia Wang
Yuxia Wang
XZXuexing Zheng
Xuexing Zheng
YZYongkun Zhao
Yongkun Zhao
XXXianzhu Xia
Xianzhu Xia

1 June 2016 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
WZWeijiao Zhang
Weijiao Zhang
XZXuexing Zheng
Xuexing Zheng
NCNan Cheng
Nan Cheng
WGWeiwei Gai
Weiwei Gai
XXXianghong Xue
Xianghong Xue
XXXianzhu Xia
Xianzhu Xia

1 December 2019 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
HXHuilin Xu
Huilin Xu
LLLulu Liu
Lulu Liu
YCYanxu Chen
Yanxu Chen
HMHao Ma
Hao Ma
MLMan Li
Man Li
YGYueqiu Gao
Yueqiu Gao

29 April 2014 in Glycoconjugate Journal
Verified
Journal Article
Closed access
PDF file
JSJunjie Shan
Junjie Shan
GSGuohui Sun
Guohui Sun
JRJinwei Ren
Jinwei Ren
TZTing Zhu
Ting Zhu
PJPeiyuan Jia
Peiyuan Jia
YWYuxia Wang
Yuxia Wang

6 December 2019 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
KLKun Liu
Kun Liu
YYYing Yin
Ying Yin
JZJun Zhang
Jun Zhang
XZXiaodong Zai
Xiaodong Zai
RLRuihua Li
Ruihua Li
WCWei Chen
Wei Chen
Polysaccharides isolated from natural plants may represent a novel source of vaccine adjuvants. In this research, we focused on a natural plant polysaccharide, PCP-I, which is derived from Poria cocos, a Chinese traditional herbal medicine. We chose the anthrax protective antigen (PA) as a model to evaluate the adjuvant ability of PCP-I in enhancing the immunogenicity and protection of a PA-based anthrax vaccine. According to our results, PCP-I could significantly enhance anthrax specific anti-PA antibodies, toxin-neutralizing antibodies, anti-PA antibody affinity, as well as IgG1 and IgG2a levels. Besides, PCP-I increased the frequency of PA-specific memory B cells, increased the proliferation of PA-specific splenocytes, significantly stimulated the secretion of IL-4, and enhanced the activation of Dendritic cells (DCs) in vitro. The combination of PCP-I and CpG significantly enhanced the level of anti-PA antibodies and neutralizing antibodies, particularly PA-specific IgG2a, and shifted the Th2-bias to a Th1/Th2 balanced response. In addition, PCP-I with or without CpG could significantly improve the survival rate of immunized mice following challenge with the anthrax lethal toxin. These findings suggest that PCP-I may be a promising vaccine adjuvant that warrants further study.